Refine by MP, party, committee, province, or result type.

Results 1-5 of 5

Finance committee  There are two areas where we can help. On the health care side, every dollar spent on pharmaceuticals saves seven dollars in downstream medical care costs, so anything that helps us along the lines of the clinical trials assistance or faster approvals on the Health Canada side h

October 18th, 2010Committee meeting

Wendy Zatylny

Finance committee  We're losing out on a lot. Our industry is, at its heart, a knowledge-based industry, and intellectual property protection is very much at the heart of the sustainability of the industry and its ability to innovate. So by Canada falling behind in a number of areas—and you'll see

October 18th, 2010Committee meeting

Wendy Zatylny

Finance committee  We can get the research brought into Canada to create jobs and bring in more investment.

October 18th, 2010Committee meeting

Wendy Zatylny

Finance committee  Absolutely, and thank you for the question. The current regulations provide a system that encourages the resolution of patent infringement issues before a generic drug actually enters the market. Often this is done through litigation. Under the current system, if a judgment goes

October 18th, 2010Committee meeting

Wendy Zatylny

Finance committee  Thank you, Mr. Chairman, and good afternoon. My name is Wendy Zatylny, and I'm vice-president of government affairs at Rx&D, Canada's Research-Based Pharmaceutical Companies. With me today is Rob Livingston, director of government relations at Merck Frosst Canada Ltd. We a

October 18th, 2010Committee meeting

Wendy Zatylny